Log in
Enquire now
‌

US Patent 10660968 Spirocyclic degronimers for target protein degradation

Patent 10660968 was granted and assigned to C4 Therapeutics on May, 2020 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
C4 Therapeutics
C4 Therapeutics
0
Date Filed
November 9, 2018
0
Date of Patent
May 26, 2020
0
Patent Applicant
C4 Therapeutics
C4 Therapeutics
0
Patent Application Number
16186334
0
Patent Citations Received
‌
US Patent 12091397 Dihydroquinolinones for medical treatment
0
‌
US Patent 11524949 Degraders and Degrons for targeted protein degradation
0
‌
US Patent 11459335 N/O-linked Degrons and Degronimers for protein degradation
0
‌
US Patent 11560381 Compounds and uses thereof
‌
US Patent 10905768 Heterocyclic degronimers for target protein degradation
‌
US Patent 11584748 Spirocyclic compounds
‌
US Patent 11691972 Compounds for targeted degradation of BRD9
0
‌
US Patent 11767330 Citrate salt, pharmaceutical compositions, and methods of making and using the same
‌
US Patent 11773085 Methods and compounds for treating disorders
‌
US Patent 11787800 BRD9 degraders and uses thereof
•••
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
10660968
0
Patent Primary Examiner
‌
Rei Tsang Shiao
0

Find more entities like US Patent 10660968 Spirocyclic degronimers for target protein degradation

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.